Regeneron joins IQ Consortium
The IQ Consortium is excited to welcome its newest member, Regeneron.
Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases.
Regeneron will be represented on the IQ Board of Directors by Dean Liu and Kenneth Graham.